Climb Bio, Inc.
NASDAQ: CLYM0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Aoife Brennan BCh MMSc
- Employees
- 17
- Headquarters
- Wellesley Hills, United States
- IPO year
- 2021
- Market cap
- $869.4M
- Website
- https://eliemtx.com
Loading CLYM…
Loading profile data…Frequently asked questions about CLYM
What does Climb Bio, Inc. (CLYM) do?
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus n...
Where does CLYM trade?
Climb Bio, Inc. (CLYM) trades on the NASDAQ Global Market.
What sector is CLYM in?
Climb Bio, Inc. (CLYM) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Climb Bio, Inc.?
Aoife Brennan BCh MMSc is the chief executive officer of Climb Bio, Inc. (CLYM).
Where is Climb Bio, Inc. headquartered?
Climb Bio, Inc. is headquartered in United States.
Does CLYM pay a dividend?
Climb Bio, Inc. (CLYM) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CLYM go public?
Climb Bio, Inc. (CLYM) completed its initial public offering in 2021.